Sanofi is in the midst of building out a new blood disorder franchise after completing its acquisition of Bioverativ Inc. in 2018 and launching the rare blood disease treatment Cablivi this year. The business area is expected to be a big growth driver for the company, but it’s also a competitive field that Sanofi will have to navigate.
Sanofi Genzyme exec VP Bill Sibold talked to Scrip in an interview in New York on 14 May about building...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
